Paolo A. Ascierto, MD, on Metastatic Melanoma: Ipilimumab Study Results
2016 ESMO CongressPaolo A. Ascierto, MD, of the Istituto Nazionale Tumori–Fondazione Pascale, discusses overall survival and safety results from a phase III trial of ipilimumab at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma. (Abstract 1106O)
Related Videos
Martin H. Schuler, MD, on Gastric and Gastroesophageal Junction Adenocarcinoma: Results of the FAST Study
Martin H. Schuler, MD, of the University Hospital Essen, discusses findings from this phase II trial of epirubicin, oxaliplatin, and capecitabine with or without the antibody IMAB...
Giorgio V. Scagliotti, MD, PhD, on ALK-Rearranged NSCLC: Results From the ASCEND-5 Trial (Italian Language Version)
Giorgio V. Scagliotti, MD, PhD, of the University of Torino, discusses in Italian study findings on ceritinib vs chemotherapy in patients with advanced ALK-rearranged non–sma...
Sian A. Pugh, MBBS, on Colorectal Cancer: Long-Term Results of the FACS Trial
Sian A. Pugh, MBBS, of Southampton University Hospital, discusses 6 to 12-year findings on the scheduled use of the CEA tumor marker and CT follow-up to detect recurrence of colorecta...
Ezra E.W. Cohen, MD, on Head and Neck Cancer: Results of the ACTIVE8 Trial
Ezra E.W. Cohen, MD, of the University of California, San Diego, discusses study findings on chemotherapy plus cetuximab in combination with motolimod immunotherapy in patients with r...
Martin H. Schuler, MD, on Gastric and GEJ Adenocarcinoma: Results of the FAST Study (German Language Version)
Martin H. Schuler, MD, of the University Hospital Essen, discusses in German findings from this phase II trial of epirubicin, oxaliplatin, and capecitabine with or without the antibod...
